NOX-E36 bietet vielversprechende Entwicklungsmöglichkeiten für Augenkrankheiten mit einem hohen Bedarf an gut verträglichen Therapien mit antifibrotischer Wirkung Die antifibrotische...
NOX-E36 presents promising opportunity for development in eye diseases with a high need for well-tolerated therapies with anti-fibrotic effect Anti-fibrotic mode of action of NOX-E36 was...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.004 | -5.40540540541 | 0.074 | 0.0828 | 0.07 | 715611 | 0.07276095 | DE |
4 | -0.003 | -4.1095890411 | 0.073 | 0.0828 | 0.069 | 381798 | 0.07306317 | DE |
12 | -0.0684 | -49.4219653179 | 0.1384 | 0.1702 | 0.0611 | 624991 | 0.09867742 | DE |
26 | -0.074 | -51.3888888889 | 0.144 | 0.18 | 0.0611 | 508155 | 0.12084903 | DE |
52 | -0.176 | -71.5447154472 | 0.246 | 0.436 | 0.0611 | 674910 | 0.21584385 | DE |
156 | 0.0282 | 67.4641148325 | 0.0418 | 5.98 | 0.0398 | 341267 | 0.31860721 | DE |
260 | 0.0282 | 67.4641148325 | 0.0418 | 5.98 | 0.0398 | 341267 | 0.31860721 | DE |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관